Actively Recruiting
Registry Platform Urologic Cancer
Led by iOMEDICO AG · Updated on 2025-09-22
1930
Participants Needed
1
Research Sites
560 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with advanced renal cell carcinoma or urothelial cancer in Germany.
CONDITIONS
Official Title
Registry Platform Urologic Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female and male patients with advanced renal cell carcinoma or advanced urothelial carcinoma (locally advanced, inoperable, or metastatic)
- Patients starting their first-line systemic treatment for advanced renal cell carcinoma or urothelial carcinoma
- Written informed consent provided
- Patients in the PRO module must sign informed consent and complete baseline questionnaire before initial systemic treatment
- Patients not in the PRO module may join within 12 weeks after starting systemic first-line treatment
- Age 18 years or older
- Histologically confirmed muscle-invasive urothelial carcinoma of the lower or upper urinary tract
- Radical surgery performed between October 1, 2021 and October 31, 2024
- High risk of recurrence based on pathological tumor status post-surgery (specific tumor and node stages without metastases)
- Age 18 years or older at time of surgery
- Written informed consent if alive at data entry (not applicable for deceased patients)
You will not qualify if you...
- Prior systemic therapy for advanced renal cell carcinoma or urothelial carcinoma
- No systemic treatment for advanced renal cell carcinoma or urothelial carcinoma
- Partial cystectomy or partial nephrectomy as definitive therapy for muscle-invasive urothelial carcinoma
- Metastatic disease at the time of surgery (M1)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Multiple sites, Germany
Multiple Locations, Germany
Actively Recruiting
Research Team
M
Michaela Koska
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here